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Objective. The aim of this study was to determine the distribution and demographic features of salivary gland tumors (SGTs)
in a large Brazilian population.
Study Design. A total of 493 cases of SGTs diagnosed between 2001 and 2011 from a general pathology laboratory and an
oral pathology service were reviewed with respect to their clinicopathologic features.
Results. A total of 369 tumors were benign and 124 were malignant. The mean age of patients with benign tumors was 46.3
years and that of patients with malignancies was 54.0 years. The parotid gland was the most common location (42.3%).
Pleomorphic adenoma (PA) and Warthin’s tumor were the most common benign neoplasias, whereas mucoepidermoid
carcinoma (MEC) and adenocarcinoma, not otherwise specified, were the most frequent malignancies.
Conclusions. The present data confirm that PA and MEC are the most common benign and malignant SGTs. However, it is
important to consider that differences in tumor types may be influenced by whether a tumor derives from a medical or a
dental service. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:230-239)Salivary gland tumors (SGTs) consist of a group of
heterogeneous lesions with complex clinicopathologic
characteristics and distinct biological behavior that cor-
respond to approximately 3% to 10% of the neoplasms
of the head and neck region.1-3 According to the World
Health Organization (WHO), the global annual inci-
dence, when all SGTs are considered, varies from 0.4 to
13.5 cases per 100 000 inhabitants, which accounts for
only 0.3% of all malignancies in the United States.4
However, reports from numerous regions of the world
have shown differences in the incidence and frequency
of tumor types, indicating a geographic variation in the
frequency of these neoplasias5,6 (Figure 1).
Although many retrospective studies regarding the
incidence of salivary gland tumors have been reported,
the epidemiology of these neoplasms is not well estab-
lished because these studies are frequently restricted to
a specific population,7,8 an anatomical location,9 or a
specific tumor type.10 In addition, differences can be
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230found in the frequency of SGTs derived from surgical
pathology centers and those from oral pathology labo-
ratories. Therefore, the objective of the current study is
to retrospectively review the characteristics of 493
SGTs retrieved from one general pathology service and
one oral pathology laboratory, both located in the
Southern Brazil, and to evaluate the clinicopathological
differences between these two samples.
MATERIAL AND METHODS
The files of a private general pathology service in
Cascavel, Paraná State, and of the Department of Oral
Pathology of the Piracicaba Dental School were retro-
spectively reviewed. During an 11-year period, be-
tween January 2001 and December 2011 (surgical pa-
thology 2001-09 and oral pathology 2002-11), 493
cases of salivary gland tumors were retrieved from both
archives. Clinical data concerning age, gender, and
tumor location were obtained from clinical charts. Mi-
croscopic slides of all cases were reviewed by three
Statement of Clinical Relevance
Numerous reports from different geographic re-
gions have shown differences in the incidence and
frequency of salivary gland tumors, and a better
understanding of their demographic data is helpful
for improving the comprehension of the clinico-
pathologic characteristics of these tumors.
ong d
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Volume 114, Number 2 Fonseca et al. 231independent oral pathologists and, if necessary, new
sections were prepared and stained with hematoxylin
and eosin, periodic acid-Schiff, or mucicarmine. All
cases were classified according to the 2005 WHO His-
tologic Typing of Salivary Gland Tumors.4
The current study was approved by the Ethical Com-
mittee of the Piracicaba Dental School, State University
Fig. 1. Heterogeneous distribution of the most frequent sal
carcinoma [MEC], and adenoid cystic carcinoma [ACC]) am
Table I. Histologic and gender distribution of 493 sal
n  493 %
Benign tumors
Pleomorphic adenoma 314 63.6
Warthin’s tumor 36 7.3
Canalicular adenoma 11 2.2
Cystadenoma 3 0.6
Myoepithelioma 3 0.6
Basal cell adenoma 1 0.2
Oncocytoma 1 0.2
Total 369 74.7
Malignant tumors
Mucoepidermoid carcinoma 39 7.9
Adenocarcinoma, NOS 33 6.6
Adenoid cystic carcinoma 22 4.4
PLGA 14 2.8
CExAP 8 1.6
Acinic cell carcinoma 5 1.0
EMC 2 0.4
Myoepithelial carcinoma 1 0.2
Total 124 25.1
CExAP, carcinoma ex-adenoma pleomorphic; EMC, epithelial-myo
low-grade adenocarcinoma.of Campinas (Protocol 141/2011).RESULTS
General overview
Of the total of 493 cases, 369 (74.8%) were benign and
124 (25.1%) malignant (a ratio of 2.9:1), distributed
among 7 benign and 8 malignant histologic subtypes,
accounting for 5.0% of all benign and malignant head
and neck neoplasias detailed by both centers (Table I).
land tumors (pleomorphic adenoma [PA], mucoepidermoid
ifferent geographic regions of the world.
gland tumors
e group of benign
alignant tumors
Gender
Male Female
n % n %
85.0 123 24.9 191 38.7
9.7 27 5.4 9 1.8
2.9 5 1.0 6 1.2
0.8 0 0.0 3 0.6
0.8 0 0.0 3 0.6
0.2 0 0.0 1 0.2
0.2 1 0.2 0 0.0
100 156 31.5 213 43.1
31.4 16 3.2 23 4.6
26.6 23 4.6 10 2.0
17.7 11 2.2 11 2.2
11.2 5 1.0 9 1.8
6.4 5 1.0 3 0.6
4.0 3 0.6 2 0.4
1.6 1 0.2 1 0.2
0.8 0 0.0 1 0.2
100 64 13.1 60 12.1
al carcinoma; NOS, not otherwise specified; PLGA, polymorphousivary givary
% in th
or m
epitheliThe overall male-to-female ratio was 0.8:1 (220 male
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portion was 0.7:1 (156 male vs 213 female) and in the
malignant cases 1.1:1 (64 males vs 60 female; Table I).
Most tumors occurred in patients 31 to 70 years old,
with an average age of 48.2 years (range 8-88 years).
The mean age of the patients with benign tumors was
46.3 years and that of those with malignancies was 54.0
years. The exact distribution of each SGT, according to
the age of the patients, is depicted in Table II.
The parotid gland was the most commonly affected
location, with a frequency of 42.3%, followed by the
palate (19.2%), lips (7.7%), and the submandibular
gland (6.8%). No tumors of the sublingual gland were
found. Benign tumors predominated in the parotid
glands, followed by the palate and lips, whereas ma-
lignancies were more frequent in the palate, parotid
gland, cheek, and submandibular gland (Table III).
Among the 369 benign salivary gland tumors, 314
were pleomorphic adenomas (PA) (63.6% of the total
or 85.0% of the benign) and 36 Warthin’s tumors (7.3%
of the total or 9.7% of the benign), and these repre-
sented the most common benign neoplasias. The most
common malignant tumors were mucoepidermoid car-
cinomas (MEC; n  39, 7.9% of the total or 31.4% of
the malignant), followed by adenocarcinomas, not oth-
erwise specified (NOS; n  33, 6.6% of the total or
26.6% of the malignant), and adenoid cystic carcino-
mas (n  22, 4.4% of the total or 17.7% of the malig-
Table II. Distribution of 493 benign and malignant sa
0-10 11-20 21-30 31-40
n % n % n % n %
Benign tumors
Pleomorphic adenoma 3 0.6 20 4.0 49 9.9 74 15
Warthin’s tumor 0 0.0 0 0.0 0 0.0 1 0
Canalicular adenoma 0 0.0 0 0.0 0 0.0 0 0
Basal cell adenoma 0 0.0 0 0.0 0 0.0 0 0
Cystadenoma 0 0.0 0 0.0 0 0.0 0 0
Myoepithelioma 0 0.0 0 0.0 1 0.2 0 0
Oncocytoma 0 0.0 0 0.0 0 0.0 0 0
Subtotal 3 0.6 20 4.0 50 10.1 75 15
Malignant tumors
Mucoepidermoid
carcinoma
0 0.0 2 0.4 4 0.8 7 1
Adenocarcinoma, NOS 0 0.0 0 0.0 1 0.2 3 0
Adenoid cystic
carcinoma
0 0.0 0 0.0 0 0.0 6 1
PLGA 0 0.0 0 0.0 0 0.0 1 0
CExAP 0 0.0 0 0.0 0 0.0 0 0
Acinic cell carcinoma 0 0.0 0 0.0 0 0.0 3 0
EMC 0 0.0 0 0.0 0 0.0 1 0
Myoepithelial
carcinoma
0 0.0 0 0.0 0 0.0 1 0
Subtotal 0 0.0 2 0.4 5 1.0 22 4
Total 3 0.6 22 4.4 55 11.1 97 19
CExPA, carcinoma ex-pleomorphic adenoma; EMC, epithelial-myo
adenocarcinoma.nant).Dental hospital sample
In a 10-year period (2002 to 2011), there were 161
salivary gland tumors diagnosed at the oral pathology
department of the Piracicaba Dental School, which
corresponded to 6.4% of all head and neck tumors
diagnosed by this department. Of these, 88 were benign
(54.1%) and 73 (45.9%) were malignant, with a benign-
to-malignant ratio of 1.2:1, representing four histo-
pathological benign subtypes and seven malignant sub-
types (Table IV).
Most tumors occurred in patients 31 to 50 years old
(mean age 48.9 years, range 8-88 years) and the male-
to-female ratio was 0.7:1. The minor glands in the
palate were the most common site (n  86 or 53.4%),
followed by the lips (n  33 or 20.4%) and the cheek
(n  15 or 9.3%; Figure 2). Pleomorphic adenoma was
the most frequent histologic type (n  73 or 45.3%),
followed by canalicular adenoma (n  9 or 5.5%). The
most common malignant tumor was MEC (n  35 or
21.7%), followed by polymorphous low-grade adeno-
carcinomas (PLGA; n  14 or 8.6%) and adenoid
cystic carcinomas (n  12 or 7.4%).
Private general pathology sample
In a 9-year period (2001 to 2009), 332 salivary gland
tumors were found in a private general pathology center
located in the city of Cascavel (Paraná State, Brazil),
accounting for 4.6% of the head and neck neoplasias
gland tumors according to age (years)
41-50 51-60 61-70 71-80 81-90 NS
% n % n % n % n % n %
11.1 47 9.5 40 8.1 15 3.0 5 1.0 6 1.2
1.2 9 1.8 13 2.6 5 1.0 1 0.2 1 0.2
0.2 3 0.4 0 0.0 7 1.4 0 0.0 0 0.0
0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0
0.2 1 0.2 0 0.0 1 0.2 0 0.0 0 0.0
0.2 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0
0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0
12.9 61 12.3 55 11.1 28 5.6 6 1.2 7 1.4
2.2 3 0.6 6 1.2 6 1.2 0 0.0 0 0.0
0.4 9 1.8 7 1.4 5 1.0 3 0.6 3 0.6
0.4 2 0.4 7 1.4 3 0.6 1 0.2 1 0.2
0.6 2 0.4 6 1.2 2 0.4 0 0.0 0 0.0
0.4 1 0.2 5 1.0 0 0.0 0 0.0 0 0.0
0.2 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0
0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0
0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
4.2 18 3.6 32 6.4 16 3.2 4 0.8 4 0.8
17.2 79 16.0 87 17.6 44 8.9 10 2.0 11 2.2
ial carcinoma; NS, not specified; PLGA, polymorphous low-gradelivary
n
.0 55
.2 6
.0 1
.0 0
.0 1
.0 1
.0 0
.2 64
.4 11
.6 2
.2 2
.2 3
.0 2
.6 1
.2 0
.2 0
.4 21
.6 85
epithelseen at this center. Of these, 281 were benign (84.6%)
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malignant ratio of 5.5:1, distributed between five be-
nign and six malignant subtypes (Table V).
Patients 31 to 70 years old were the most affected,
with a mean age of 47.7 years (range 8-86 years) and a
Table III. Distribution of the 493 salivary gland tumor
Major salivary glands
Parotid Submandibular Sublingual
n % n % n %
Benign tumors
Pleomorphic adenoma 153 31.0 24 4.8 0 0.0
Warthin’s tumor 29 5.8 1 0.2 0 0.0
Canalicular adenoma 0 0.0 0 0.0 0 0.0
Cystadenoma 0 0.0 0 0.0 0 0.0
Myoepithelioma 0 0.0 0 0.0 0 0.0
Basal cell adenoma 1 0.2 0 0.0 0 0.0
Oncocytoma 1 0.2 0 0.0 0 0.0
Subtotal 184 37.3 25 5.0 0 0.0
Malignant tumors
Mucoepidermoid
carcinoma
3 0.6 0 0.0 0 0.0
Adenocarcinoma, NOS 17 3.4 3 0.6 0 0.0
Adenoid cystic
carcinoma
2 0.4 4 0.8 0 0.0
PLGA 0 0.0 0 0.0 0 0.0
CExAP 1 0.2 2 0.4 0 0.0
Acinic cell carcinoma 2 0.4 0 0.0 0 0.0
EMC 0 0.0 0 0.0 0 0.0
Myoepithelial
carcinoma
0 0.0 0 0.0 0 0.0
Subtotal 25 5.0 9 1.8 0 0.0
Total 209 42.3 34 6.8 0 0.0
CExPA, carcinoma ex-pleomorphic adenoma; EMC, epithelial-myo
adenocarcinoma.
Table IV. Histologic and gender distribution of 161 sali
São Paulo State, Brazil
n  161 %
Benign tumors
Pleomorphic adenoma 73 45.3
Canalicular adenoma 9 5.5
Cistadenoma 3 1.8
Myoepithelioma 3 1.8
Total 88 54.6
Malignant tumors
Mucoepidermoid carcinoma 35 21.7
PLGA 14 8.6
Adenoid cystic carcinoma 12 7.4
Adenocarcinoma, NOS 6 3.7
Acinic cell carcinoma 2 1.2
EMC 2 1.2
CExAP 2 1.2
Total 73 45.3
CExAP, carcinoma ex-adenoma pleomorphic; EMC, epithelial-myo
low-grade adenocarcinoma.male-to-female ratio of 0.8:1. The parotid gland was byfar the most affected site (62.6%), followed by the
submandibular gland (10.5%) and the minor glands in
the palate (2.7%; Figure 3). Pleomorphic adenoma was
the most frequent histologic type (n  241 or 72.5%),
followed by Warthin’s tumor (n  36 or 10.8%). Ad-
rding to the location (major and minor salivary glands)
Minor salivary glands
Floor of
the mouth NSlate Lips
Cheek
mucosa Tongue
% n % n % n % n % n %
10.9 20 4.0 7 1.4 0 0.0 0 0.0 56 11.3
0.0 0 0.0 0 0.0 0 0.0 0 0.0 6 1.2
0.2 10 1.8 0 0.0 0 0.0 0 0.0 0 0.0
0.2 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2
0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
11.9 30 6.0 7 1.4 0 0.0 1 0.0 63 12.7
4.2 1 0.2 2 0.4 2 0.4 1 0.2 9 1.8
0.4 0 0.0 1 0.2 0 0.0 0 0.0 10 2.0
0.8 1 0.2 3 0.6 2 0.4 0 0.0 6 1.2
1.4 4 0.8 2 0.4 0 0.0 0 0.0 1 0.2
0.2 1 0.2 0 0.0 0 0.0 0 0.0 3 0.6
0.0 1 0.2 1 0.2 0 0.0 0 0.0 1 0.2
0.2 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0
0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2
7.3 8 1.6 10 2.0 4 0.8 1 0.0 31 6.2
19.2 38 7.7 17 3.4 4 0.8 2 0.4 94 19.0
ial carcinoma; NS, not specified; PLGA, polymorphous low-grade
land tumors diagnosed at the Piracicaba Dental School,
the group of benign
malignant tumors
Gender
Male Female
n % n %
82.9 33 20.5 40 24.8
10.2 4 2.5 5 3.1
3.4 0 0.0 3 1.9
3.4 0 0.0 3 1.9
100 37 23.0 51 31.7
47.9 15 9.3 20 12.4
19.1 5 3.1 9 5.6
16.4 5 3.1 7 4.3
8.2 2 1.2 4 2.5
2.7 1 0.6 1 0.6
2.7 1 0.6 1 0.6
2.7 2 1.2 0 0.0
100 31 19.2 42 26.0
al carcinoma; NOS, not otherwise specified; PLGA, polymorphouss acco
Pa
n
54
0
1
1
3
0
0
59
21
2
4
7
1
0
1
0
36
95
epithelvary g
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epithelienocarcinoma NOS was the most common malignant
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ecified
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carcinoma (n  10 or 3.0%) and carcinoma ex-pleo-
morphic adenoma (n  6 or 1.8%).
Major versus minor salivary glands
Examination of the distribution of SGTs affecting ma-
jor and minor salivary glands indicated that 243 neo-
plasias were located in the major glands and 156 in the
minor glands (1.5:1 ratio; in 94 cases the location was
not specified; Table III). There were only 2 cases af-
fecting major glands in the sample derived from the
oral pathology center (1.2%), both found in the parotid
Fig. 2. Distribution of 161 salivary gland tumors diagnosed b
according to the primary site of involvement. NS, not specifi
Table V. Histologic and gender distribution of the 3
Pathology Center, Cascavel, Paraná State, Brazil
n  332 %
Benign tumors
Pleomorphic adenoma 241 72.5
Warthin’s tumor 36 10.8
Canalicular adenoma 2 0.6
Basal cell adenoma 1 0.3
Oncocitoma 1 0.3
Total 281 84.6
Malignant tumors
Adenocarcinoma, NOS 27 8.1
Adenoid cystic carcinoma 10 3.0
CExAP 6 1.8
Mucoepidermoid carcinoma 4 1.2
Acinic cell carcinoma 3 0.9
Myoepithelial carcinoma 1 0.3
Total 51 15.3
CExAP, carcinoma ex-adenoma pleomorphic; NOS, not otherwise spgland, whereas 86.9% of the tumors affected minorglands, and in 11.8% of the cases the location was not
specified. On the other hand, tumors of the major
glands accounted for 72.5% of the neoplasias diag-
nosed in the general pathology center (62.3% affecting
the parotid and 10.2% the submandibular glands),
whereas 4.8% of the tumors affected minor glands and
in 22.5% of the cases the location was unspecified. In
major glands there was a significantly higher benign-
to-malignant ratio than that observed in minor glands
(6.1:1 vs 1.6:1, respectively).
Pleomorphic adenoma was the most common benign
tumor in both major and minor glands (72.8% [177 of
epartment of Oral Pathology of the Piracicaba Dental School
ivary gland tumors diagnosed at the Private Surgical
e group of benign
alignant tumors
Gender
Male Female
n % n %
85.7 91 27.4 150 45.1
12.8 27 8.1 9 2.7
0.7 0 0.0 2 0.6
0.3 0 0.0 1 0.3
0.3 1 0.3 0 0.0
100.0 119 35.7 162 48.7
52.9 21 6.3 6 1.8
19.6 6 1.8 4 1.2
11.7 3 0.9 3 0.9
7.8 1 0.3 3 0.9
5.8 2 0.6 1 0.3
1.9 0 0.0 1 0.3
100.0 33 9.9 18 5.4
.y the D32 sal
% in th
or m243 cases] and 51.9% [81 of 156 cases], respectively),
ed.
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the 243 major glands tumors) and canalicular adenoma
in minor glands (7.0% of the 156 cases affecting minor
glands). Regarding malignancies, adenocarcinoma
NOS and adenoid cystic carcinoma were the most fre-
quent neoplasias of the major glands (8.2% and 1.2%,
respectively), whereas MEC and PLGA represented the
most common malignancies in minor glands (17.3%
and 8.3%, respectively).
DISCUSSION
Salivary gland tumors are a large and diverse group of
lesions, characterized by morphologic heterogeneity.
There are numerous epidemiologic studies of SGTs in
different countries, with varied results likely represent-
ing differences in the origin of the study (medical or
dental centers), divergences in the histologic classifica-
tion, restriction to a specific population, anatomical
location, or tumor type6,7,11-34 (Tables VI and VII).
Herein, we assessed 493 cases of SGTs from one med-
ical and one oral pathology laboratory located in south-
ern Brazil with the aims of investigating the distribution
and clinicopathologic features of these neoplasias. Al-
though there was some variability, particularly regard-
ing the palate as the most affected site by malignancies,
the results obtained revealed that the tumor types and
their demographic features are in agreement with nu-
merous reports, including those previously reported in
Brazil.1,3,5,35
According to the WHO, female patients are slightly
more affected than males, although some variation can
be found when analyzing specific tumor types.4 In the
Fig. 3. Distribution of 332 salivary gland tumors diagnosed
according to the primary site of involvement. NS, not specificurrent study the male-to-female ratio was 0.8:1, whichis in accordance with the majority of studies, including
Brazilian reports,1,3,5,12,14,24,27,35 although several re-
ports have shown an increased frequency in male pa-
tients.15,36-38 It should be considered that benign tumors
presented a male-to-female ratio of 0.7:1, whereas malig-
nant neoplasias demonstrated a ratio of 1.1:1, indicating
that benign tumors were slightly more common in fe-
males, whereas malignancies more often occurred in
males, in accordance with previous studies.3,5,14,26 How-
ever, this is in contrast to results previously reported in
Mexico,21 where female patients were more frequently
affected by malignancies than male patients.
The age distribution in the present survey varied
from 8 to 88 years old, with a mean age of 48.2 years,
similar to other studies.3,12,21 As reported previ-
ously,3,15 the mean age of patients with malignant neo-
plasias is about a decade higher than that for benign
tumors. However, Jansisyanont et al. (2002) reported
that patients affected by malignant tumors were on
average 6 years younger than those affected by benign
neoplasias.25
In the majority of studies, and in those derived from
medical centers, the parotid gland is by far the most
commonly affected location, with 64% to 80% of all
primary SGTs occurring at this site, more specifically
in the superficial lobe.38,39 In the present study the
parotid gland was also the most commonly affected site
(42.3%), followed by minor glands of the palate, lips,
and the submandibular gland, which is in accordance
with the observations of previous studies.6,37,38 The
parotid gland was the most common location for benign
tumors, whereas the palate was the most common site
private surgical pathology center in Cascavel (Paraná State)by afor malignancies. Although some studies conclude that
mucino
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ally more affected by malignancies than major
glands,16,20 the great majority of studies report the
parotid gland as the most affected site by both benign
and malignant neoplasias.6,14,15 However, by evaluat-
ing the distribution and demography of SGTs derived
from two distant geographic locations (Finland and
Israel), Bello et al. observed that most malignant tu-
mors commonly occurred in the parotid gland in the
Finnish centers; whereas among Israeli cases, malig-
nant tumors were more commonly seen in the minor
salivary glands, illustrating the broad differences ob-
tained when analyzing the clinical features of SGTs.38
Moreover, unlike the results of the present survey, in
many studies the submandibular gland has been
found to be the second most affected site, which is
more commonly found in studies conducted in med-
ical centers, whose samples are mainly formed by
tumors affecting major glands.1,3,15,16,40
In the present study, 74.8% of the cases were benign
Table VI. Incidence of major and minor salivary glan
Authors Country n
Benign tumo
Pleomorphic
adenoma
Warthin’s
tumor
Ca
a
Present study, 2012 Brazil 493 63.6 7.3
Velázquez et al.
201221
Mexico 360 65.5 5.5
Luksic et al. 20126 Croatia 779 47.2 11.1
Shishegar et al.
201120
Iran 392 58.0 6.0
Tian et al. 201037 East China 6982 46.9 13.8
Kara et al. 201015 Turkey 125 64.0 4.8
Tilakaratne et al.
200942
Sri Lanka 713 38.4 4.1
Ochicha et al.
200917
Nigeria 78 48.7 0.0
Oliveira et al. 20093 Brazil 599 67.8 6.3
Li et al. 200812 West China 3461 51.3 4.4
Subhashraj 200839 India 684 53.1 3.1
Jones et al. 200813 UK 741 44.4 4.6
Al-Khateeb and
Ababneh 200716
Jordan 102 54.0 4.0
Ansari 20072 Iran 130 65.4 0.0
Ito et al. 20055 Brazil 496 54.2 8.5
Lima et al. 200535 Brazil 245 68.5 6.9
Otoh et al. 200536 Nigeria 79 44.3 2.5
Vuhahula 200444 Uganda 268 39.9 0.0
Vargas et al. 20021 Brazil 124 59.0 10.5
Satko et al. 200040 Slovakia 1021 53.9 9.7
Renehan et al.
199618
UK 1194 65.0 13.0
Saku et al. 199719 Japan 120 53.3 13.3
Chidzonga et al.
199514
Zimbabwe 282 73.0 7.0
ACC, adenoid cystic carcinoma; AcCC, acinic cell carcinoma; Ad
ex-pleomorphic adenoma; EMC, epithelial-myoepithelial carcinoma
nocarcinoma.
*Basal cell adenoma and canalicular adenoma were evaluated as mo
†Included basal cell adenocarcinoma, papillary cystadenocarcinoma,and 25.1% were malignant, confirming the predomi-nance of benign SGTs.3,6,13,27,40,41 All epidemiologic
studies clearly show that PA is by far the most common
salivary gland neoplasia, both in major and in minor
glands.13,37 In this survey, PA corresponded to 63.6%
of all tumors, accounting for 72.8% of the major and
52.6% of the minor glands and mainly affecting female
patients in the fourth decade of life. The second most
common benign tumor was Warthin’s tumor, which
accounted for 7.3% of all tumors and 9.7% of benign
tumors. Because Warthin’s tumor occurs almost exclu-
sively in the parotid, it is rarely reported in studies
considering only tumors of the minor salivary glands,
and in these series, canalicular adenoma may represent
the second most common benign entity.6,9,38
In accordance with the majority of studies, MEC was
the most frequent malignant neoplasia found in the
present survey (7.9% of all tumors), corresponding to
1.2% and 17.3% of the major and minor gland neopla-
sias, respectively, and mainly diagnosed in female pa-
tients in the fifth decade of life.5,6,12,42 However, unlike
ors in different continents
Malignant tumors
r Basal cell
adenoma MEC ACC PLGA AcCC CExPA
Adenoc.
NOS EMC
0.2 7.9 4.4 2.8 1.0 1.6 6.6 0.4
2.2 4.7 5.0 0.5 2.5 1.9 0.0 0.0
0.7 8.6 12.0 0.5 3.0 4.2 2.1 0.0
0.7 8.0 13.0 0.6 1.5 0.6 1.0 1.0
3.7 9.6 9.8 0.4 2.5 2.6 1.9 0.5
0.8 2.4 8.8 0.8 0.8 1.6 4.0 0.0
1.4 21.6 13.5 4.2 2.5 3.2 3.6 0.6
2.0 23.1 3.8 5.1 1.3 0.0 0.0 0.0
0.0 5.0 6.5 0.0 0.0 0.0 6.2 0.0
1.7 7.5 7.3 1.3 2.4 4.2 6.6 0.4
1.6 7.2 9.6 0.0 2.8 3.5 4.5 0.4
5.0 11.5 8.4 3.8 2.6 3.2 1.8 0.8
0.0 8.0 13.0 0.0 4.0 1.0 1.0 0.0
8* 11.5 2.3 0.0 0.0 0.7 4.6 0.0
0.6 13.5 7.9 1.8 1.8 0.6 1.4 1.0
0.0 4.4 5.3 0.0 4.9 3.6 3.6 0.0
8* 10.1 8.9 0.0 2.5 5.1 2.5 0.0
3.4 9.3 13.4 3.7 6.0 2.2 3.7 2.2
0.8 10.5 4.0 0.0 0.8 2.4 0.8 0.8
2.5 5.2 6.4 0.0 3.9 0.8 3.5 0.0
1.0 3.0 6.0 0.0 2.0 2.0 3.0† 0.08
2.5 10.0 9.1 0.8 0.0 4.1 2.5 0.0
0.0 4.2 8.9 0.0 0.0 0.4 0.0 0.0
OS, adenocarcinoma not otherwise specified; CExPA, carcinoma
mucoepidermoid carcinoma; PLGA, polymorphous low-grade ade-
hic adenoma in these studies.
us adenocarcinoma, and adenocarcinoma, not otherwise specified.d tum
rs
nalicula
denoma
2.2
0.2
0.0
0.0
0.04
0.0
0.3
0.0
0.0
0.4
0.4
4.7
0.0
1.
0.4
0.8
3.
0.0
0.0
0.0
0.0
0.8
0.0
enoc. N
; MEC,
nomorpthe majority of the studies, in the current series adeno-
duct tra
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nant tumor, accounting for 6.6% of all tumors and
26.6% of malignant tumors.1,37 This high frequency,
nonetheless, is in accordance with that reported by
the latest series published by the Armed Forces In-
stitute of Pathology, where adenocarcinoma NOS
also represented the second most frequent malig-
nancy of salivary glands.43 This neoplasia mostly
affected the parotid gland of male patients in the
sixth and seventh decades of life. Adenoid cystic
carcinoma was the third most common malignant
tumor, accounting for 4.4% of all tumors. This inci-
dence is lower than that observed in many other
studies, where it represents the most or the second
most frequent malignant neoplasia.13,16,18,37,38,41,44 In
the present survey, adenoid cystic carcinoma usually
affected the submandibular and the palatal glands, with
equal gender distribution and predominance for the
seventh decade of life.
Not surprisingly, the main difference observed be-
tween samples derived from surgical and oral pathol-
ogy services was related to the distribution of tumors
preferentially affecting the major or minor salivary
glands. In the current study, most cases from the sur-
Table VII. Incidence of intraoral minor salivary gland
Authors Country n
Benign tumo
Pleomorphic
adenoma
Warthin’s
tumor
Ca
a
Present study, 2012 Brazil 156 51.9 0.0
Venkata and
Irulandy et al.
201131
India 185 22.1 0.0
Dhanuthai et al.
200923
Thailand 311 42.7 0.0
Buchner et al.
200741
United States 380 39.2 0.0
Pires et al. 20079 United States 546 33.2 0.0
Wang et al. 200711 China 737 37.3 0.1
Jaber et al. 200624 Libya 75 30.6 0.0
Toida et al. 200529 Japan 82 65.8 0.0
Yih et al. 200533 United States 213 43.6 0.0
Poomsawat et al.
200428
Thailand 60 30.0 0.0
Jansisyanont et al.
200225
United States 80 21.3 0.0
Lopes et al. 199926 Brazil 196 33.1 0.0
Bastidas et al.
199622
Venezuela 62 38.7 0.0
Loyola et al. 199527 Brazil 164 53.0 0.0
Van Heerden et al.
199130
South Africa 70 48.5 0.0
Waldron et al.
198832
United States 426 40.8 0.0
ACC, adenoid cystic carcinoma; AcCC, acinic cell carcinoma; Ad
ex-pleomorphic adenoma; EMC, epithelial-myoepithelial carcinoma
nocarcinoma.
*Basal cell adenoma and canalicular adenoma were evaluated as mo
†The authors included the so-called lobular polymorphous terminalgical pathology center affected major glands (72.5%),particularly the parotid, which accounted for 62.3% of
the 332 cases. In contrast, intraoral minor salivary
glands represented the most common site in the oral
pathology service, accounting for 86.9% of the 161
cases. These findings are in agreement with almost all
international series previously reported.6,26 Most epide-
miologic studies suffer this bias, as can be seen with other
diseases such as odontogenic tumors (ameloblastoma vs
odontoma) and oral cancer (studies that include cases
from lip and oropharynx vs those that do not). Thus,
although the overall distribution of SGTs in the current
study diverged from that of studies conducted in dental
hospitals, regarding only neoplasias affecting intraoral
minor glands the present results agree with the majority
of the previous studies from oral pathology services.
Such studies have observed MEC and adenoid cystic
carcinoma, or PLGA, as the most frequent malignan-
cies, and PA and canalicular adenoma as the most
common benign neoplasias,9,25,26,30,33,41 and the minor
glands of the palate as the most frequently affected
site.29,31 In addition, the benign:malignant ratio proved
to be higher in the medical sample than in the dental
one, mainly because of the higher incidence of PA in
the former, which has been reported in almost every
rs in different continents
Malignant tumors
r Basal cell
adenoma MEC ACC PLGA AcCC CExPA
Adenoc.
NOS EMC
0.0 17.3 6.4 8.4 1.2 1.2 1.9 1.2
1.0 34.0 14.5 9.7 0.0 0.5 7.5 0.0
2.8 22.8 18.3 0.6 0.0 0.6 9.3 0.3
1.6 21.8 6.3 7.1 1.6 0.5 2.1 0.0
0.0 22.9 6.4 5.1 3.8 0.4 3.8 0.4
0.5 12.4 19.4 4.6 0.9 3.0 5.6 1.4
2.6 25.3 17.3 4.0 0.0 2.6 10.6 0.0
0.0 9.7 12.1 0.0 3.6 2.4 2.4 0.0
0.0 21.1 10.3 8.4 0.5 0.9 1.9 0.0
0.0 43.3 15.0 1.7 0.0 5.0 1.7 0.0
1.2 41.3 8.8 11.3 3.8 0.0 3.8 0.0
1.5 38.7 17.3 1.5 0.5 0.0 4.5 0.0
3.2 29.0 9.7 0.0 0.0 0.0 3.2 0.0
1.0 17.0 13.0 2.0 4.0 0.0 1.0 1.0
0.0 15.2 12.8 15.7 0.0 7.1 1.4 1.4
0.7* 15.2 9.3 11.0† 3.5 1.4 0.0 0.0
OS, adenocarcinoma not otherwise specified; CExPA, carcinoma
mucoepidermoid carcinoma; PLGA, polymorphous low-grade ade-
hic adenoma in this study.
becular carcinomas.tumo
rs
nalicula
denoma
7.0
0.0
0.3
6.1
9.2
0.0
1.3
0.0
11.7
0.0
1.2
0.0
0.0
0.0
0.0
1
enoc. N
; MEC,
nomorpprevious study.6,16 By contrast, no significant differ-
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mean age of the patients between the two centers.
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